Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 26, 2007 Brian Lawler	Shire's Busy Week Shire Pharmaceuticals announces year-end results, new regulatory approval, and another acquisition.
BusinessWeek October 24, 2005 Gene G. Marcial	Undivided Attention For An ADHD Battle Sales of Shire Pharmaceuticals' Adderall XR, the leading ADHD drug, are up.
The Motley Fool October 9, 2007 Brian Lawler	Shire Slims Down, Slightly The U.K.-based pharmaceutical sells off some of its marketed drugs in order to focus more on its key ADHD franchises.
The Motley Fool July 27, 2007	Shire's Got Focus: Fool by Numbers Revenue and guidance are up at Shire, led by improved sales of their ADHD drugs.
BusinessWeek August 22, 2005 Gene G. Marcial	New River May Have A "Blockbuster" For ADHD New River Pharmaceuticals has yet to make a dime - but investors love it.
The Motley Fool August 19, 2004 Charly Travers	1 Pill for Sleep, Attention Ailments? Cephalon gets some good news about its drug PROVIGIL.
The Motley Fool May 25, 2011 David Williamson	Pay Attention to Shire The British ADHD medicine maker is busy making big moves.
The Motley Fool October 9, 2006 Brian Lawler	New Drug for New River An approvable letter from the FDA sends shares of New River Pharmaceuticals up.
The Motley Fool November 9, 2006 Brian Lawler	Noven Might Be in a Purple Patch Investors in Noven shares might as well pay most of their attention to Shire, because as long as Daytrana does well, so too will Noven.
The Motley Fool September 5, 2007 Brian Lawler	Not Your Typical Product Recall Shire and Noven will fix an annoying foible of their ADHD patch, Daytrana, making the back adhesive easier to unpeel.
The Motley Fool August 28, 2008 Brian Orelli	Me-Too Drugs: Are They Worth It? These drugs have less risk, but also usually bring less of a reward to the companies that make them.
The Motley Fool June 30, 2008 Brian Orelli	Johnson & Johnson Grows Up a Little Its Concerta for attention-deficit disorder is approved for use in adults.
Chemistry World January 26, 2015 Phillip Broadwith	Shire deepens rare disease focus with NPS buyout UK specialty pharmaceutical firm Shire has agreed to buy US biotech NPS Pharmaceuticals for $5.2 billion.
The Motley Fool April 2, 2007 Brian Lawler	Pain Therapeutics Pares Shares The small drugmaker announces a share buyback.
The Motley Fool July 12, 2007 Brian Lawler	Noven's Novel Acquisition With JDS Pharmaceuticals, the company is moving toward more traditional oral drugs. Investors, take note.
Chemistry World November 4, 2015 Phillip Broadwith	Shire to buy cardiovascular specialist Dyax The deal gives Shire access to Dyax's portfolio of approved and developmental drugs for treating hereditary angioedema.
The Motley Fool August 20, 2007 Brian Lawler	Are These Perfect Pharma Acquisitions? Weighing recent drug-industry deals' odds of success: AstraZeneca and MedImmune... Shire and New River Pharmaceuticals... Gilead and Myogen...
The Motley Fool November 3, 2010 Brian Orelli	Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits.
The Motley Fool February 26, 2007	Sales Up at Shire Pharmaceuticals: Fool by Numbers The drugmaker released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool May 12, 2008 Brian Orelli	Lowering the Barr Barr Pharmaceuticals disappoints by lowering expectations.
The Motley Fool September 2, 2010 Brian Orelli	Pfizer Takes an Orphan Into the Fold Pfizer is likely pursuing FoldRx's pipeline and expertise in rare diseases.
Chemistry World June 23, 2014 Phillip Broadwith	Shire fends off AbbVie takeover bid Shire is the latest pharmaceutical company to be targeted for a multi-billion dollar takeover deal from a firm looking to transfer its tax residence outside the US.
Chemistry World November 11, 2013 Phillip Broadwith	Shire will cut UK R&D to focus on rare diseases Shire Pharmaceuticals has begun an employee consultation process as it seeks to discontinue a significant proportion of research and development activities at its historic UK base in Basingstoke.
The Motley Fool July 28, 2009 Brian Orelli	All Growth, All the Time This generic-drug maker is no value play.
Pharmaceutical Executive June 1, 2012	Raising the Stakes in CNS As brands are required to produce more and more data to convince not only regulators, but payers, physicians, and patients, Jeffrey Jonas is pushing Shire's "search and develop" R&D model into new and sometimes uncomfortable territory.
BusinessWeek October 27, 2003 Catherine Arnst	Attention Deficit: Not Just Kid Stuff Drugmakers are starting to target an overlooked group: Adults with ADHD.
The Motley Fool February 28, 2011 Brian Orelli	Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on.
The Motley Fool February 7, 2006 Stephen D. Simpson	Barr None Bargain hunters are probably going to come up short when it comes to assessing Barr Pharmaceuticals' stock, but a fairly rich package of opportunities should keep growth strong for the immediate future.
The Motley Fool October 30, 2007 Brian Orelli	Big Pharma's Takeover Wish List Which companies may be the next big pharma buyout candidates? Investors, take note.
The Motley Fool December 26, 2006 Brian Lawler	Barely a Ripple for New River With New River's $2 billion market cap, no recurring revenues to speak of, and the terms of its partnership with Shire still uncertain, these shares are more than a tad too rich.
The Motley Fool June 21, 2005 Charly Travers	A Biotech Bargain Paying $1.6 billion for a robust pipeline and promising future may be a steal. Purchasing Transkaryotic's drug portfolio should pay off very soon for the specialty pharmaceutical Shire.
The Motley Fool August 15, 2006 Stephen D. Simpson	Twirling the Barr Look closely and you'll see that Barr posted a solid quarter. Investors, if you haven't checked this one out yet, now may be the time for a little due diligence.
The Motley Fool May 1, 2007 Brian Lawler	Pay Attention to Noven The drug developer announced results from another quarter of strong growth. Revenue doubled versus the year-ago period as sales of its attention-deficit hyperactivity disorder patch, Daytrana, began to pick up.
ifeminists May 24, 2006 Gerald K. McOscar	ADHD Is it child abuse per se for parents to allow doctors to prescribe mind altering drugs with potentially serious or fatal psychiatric side effects to their children, no matter how challenged...or challenging?
The Motley Fool November 8, 2006 Brian Lawler	Barr's Wounded Quarter If your revenues live by the generic sword, they can die by it, too. That seems to be the case today for Barr Pharmaceuticals. Investors, take note.
Pharmaceutical Executive October 1, 2005	Thought Leader: Room for Improvement An interview with Randal J. Kirk, founder of New River Pharmaceuticals, whose drug technology team has made it its goal to introduce safer, more efficacious and reliable models of existing franchise drugs.
The Motley Fool March 3, 2011 Ryan McBride	With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players.
The Motley Fool November 12, 2007 Brian Orelli	Raising the Barr Barr Pharmaceuticals' acquisition of Pliva increases sales, but it doesn't help raise the bottom line. Investors, take note.
Chemistry World November 2010	Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream?
The Motley Fool December 5, 2005 W.D. Crotty	Cashing In on Noven's Drug Patch An FDA advisory panel recommends approval of Noven's patch for attention deficit hyperactivity. For now, investors might be put off by the company's lofty valuation of 55 times trailing earnings.
The Motley Fool May 5, 2010 Brian Orelli	Teva's Double-Edged Sword Nice quarter, but where will future growth come from?
Pharmaceutical Executive August 1, 2013 William Looney	Succinctly Shire: An Interview with CEO Flemming Ornskov Shire's new CEO has a simple strategy for success: Set the pace on specialty medicines, spread the positive buzz and momentum of a growth stock, and seize the opportunity to innovate.
The Motley Fool May 2, 2007 Mike Havrilla	Consider Cortex New findings may give Cortex's ADHD drug the lift it needs. The news represents an excellent opportunity for speculative biotech investors
The Motley Fool August 31, 2011 Brian Orelli	Shire Enters a Crowded Market Last week, the FDA approved Shire Pharmaceuticals' Firazyr to treat a rare genetic disease.
The Motley Fool February 3, 2010 Brian Orelli	Pfizer's Hedge Pays Off FDA wants more data from Pfizer's partner, Protalix on their treatment for Gaucher disease.
BusinessWeek March 27, 2006 Gene G. Marcial	Cortex Draws A Bead On Hyperactivity When Cortex Pharmaceuticals disclosed on Mar. 8 that its lead drug, CX717, showed favorable results in Phase 2 trials for the treatment of adult ADHD, the stock jumped.
The Motley Fool June 18, 2009 Brian Orelli	Your Stocks Just Got Riskier It's been a busy week for the Food and Drug Administration, and not in the bust-out-the-champagne-we-got-an-approval way. Is the FDA cracking down on pharmaceutical companies?
The Motley Fool August 7, 2008 Brian Orelli	The Next Pharma Acquisition The rate of mergers and acquisitions among drugmakers has reached a feverish pace lately, and doesn't show any signs of slowing down anytime soon. Take a look at some likely candidates.
The Motley Fool November 22, 2005 Brian Gorman	Saying No to Drugs Britain's policy of restricting drug access based on cost-benefit analyses should be on the radar screen of pharmaceutical investors.
Managed Care June 2006	More Young Adults Prescribed ADHD Drugs The number of adults ages 20 to 44 prescribed attention deficit hyperactivity disorder medications increased about 140% from 2000 to 2005. This was even faster growth than the 82% reported for children.